ArticleMedicina (Kaunas, Lithuania)2025
An Unusual Case of Metastatic Gastric Cancer Presenting with Right Heart Failure and Cardiac Metastasis.
Article in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac metastasis is rarely detected in oncology practice. Herein we present a rare case of metastatic gastric cancer that metastasized to the right atrium and presented with right heart failure. A 51-year-old male patient with no known chronic disease presented with fatigue, abdominal distension and leg edema for 3 weeks. Physical examination revealed abdominal ascites, tachycardia and pretibial edema. Transthoracic echocardiography (TTE) revealed a hypoechoic, less-mobile mass that almost completely filled the right atrium. Moreover, 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) showed metastatic lesions and a primary tumor-suspicious area in the esophagogastric component. Upper GI endoscopic evaluation performed on the patient revealed an ulcerovegetating mass consistent with gastric adenocarcinoma. A human epidermal growth factor receptor 2 (HER-2) was positiveand programmed death-ligand 1 (PD-L1) combined positive score (CPS) was detected as 15 in immunohistochemistry (IHC). Thereafter, an anticoagulant treatment was started including pembrolizumab and trastuzumab every three weeks, and an oxaliplatin and 5-FU-based chemotherapy regimen was started every two weeks. There was no regression in the cardiac lesion during follow-up; thereafter, there was a significant risk of cardioembolic complications, and a 10 × 7 cm mass filling the right atrium and adhering to the inferior vena cava was resected. The pathology results of the excision material reported gastric carcinoma metastasis. Systemic evaluation performed 3 months later showed regression in primary and metastatic lesions. Cardiac metastases are rare and may not be discovered until autopsy due to the prominence of primary disease findings. Cardiac metastasis, although rare, should be kept in mind in gastric cancer patients presenting with heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.